Peer-reviewed preclinical melanoma research finds Provectus’s synthetic small molecule can both stimulate anti-tumor immunity and suppress peripheral immune cells at the same dose.
Through predictive modelling, AI supports target identification, prediction of physicochemical properties and formulation strategy selection.
FDA’s PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results